Type 1 immunity relies on the differentiation of two major subsets of T lymphocytes, the CD4 ؉ T helper (Th) cell and the CD8 ؉ cytotoxic T cell, that direct inflammatory and cytotoxic responses essential for the destruction of intracellular and extracellular pathogens. In contrast to CD4 cells, little is known about transcription factors that control the transition from the CD8 naïve to effector cell stage. Here, we report that the transcription factor T-bet, known to regulate Th cell differentiation, also controls the generation of the CD8 ؉ cytotoxic effector cell. Antigen-driven generation of effector CD8 ؉ cells was impaired in OT-I T cell receptor transgenic mice lacking T-bet, resulting in diminished cytotoxicity and a marked shift in cytokine secretion profiles. Furthermore, mice lacking T-bet responded poorly to infection with lymphocytic choriomeningitis virus. T-bet is a key player in the generation of type 1 immunity, in both Th and T cytotoxic cells.
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T he development, differentiation, and activation of the CD8 ϩ cytotoxic T lymphocyte (CTL) are fundamental to the successful clearance of most pathogenic microorganisms. Upon stimulation, naïve CD8 ϩ T cells undergo rapid antigen-specific selection, expansion, and differentiation, generating a concerted population of effector CTLs (1) . Compared to the naïve precursor, the effector CD8 ϩ T cell exhibits a distinct profile of surface markers and effector molecules required for pathogen eradication (2) . Once an infection has been successfully cleared, the effector cell population diminishes rapidly through extensive cell death, while maintaining a pool of long-lived memory cells. Although the course of a CD8 ϩ T cell response has been described for numerous pathogens, the factors that control the transition of a naïve CD8 ϩ precursor to an activated, lytic effector cell are poorly understood (3) . Stat4, for example, whose activation by IL-12 or IFN-␣ in CD8 ϩ T cells does modulate IFN-␥ production, has not been reported to affect CTL function (4, 5) .
T-bet, a T helper 1 (Th1)-specific transcription factor previously isolated and characterized in this laboratory, has been shown to be required for the development of the CD4 ϩ Th1 subset. T-bet directly activates transcription of the IFN-␥ gene and has the remarkable property of redirecting committed Th2 populations to a Th1 phenotype (6) . The importance of T-bet in Th1 immunity has been most clearly illustrated through the analysis of mice with a targeted disruption of the T-bet locus. CD4 ϩ T cells lacking T-bet are severely impaired in their ability to produce IFN-␥, yet secrete elevated levels of the opposing Th2 subset cytokines, IL-4 and IL-5 (7). Furthermore, T-betdeficient mice, on the otherwise resistant C57BL͞6 background, are highly susceptible to Leishmania major infection, are protected from autoimmune inflammatory bowel disease, and spontaneously develop inflammation and airway remodeling resembling human asthma, indicating a marked in vivo shift of the Th1͞Th2 balance toward the Th2 pathway (7) (8) (9) .
Interestingly, in our initial analysis, whereas CD4 ϩ T cell function was greatly impaired in the absence of T-bet, CD8 ϩ T cells were unaffected by the loss of T-bet, as assessed by their production of IFN-␥ and cytolytic activity in vitro (7) . This finding was unexpected given that T-bet is rapidly induced to comparable levels in both cell types by signals emanating from the IFN-␥ receptor and T cell receptor (TCR) (7, 10, 11) . However, it has been pointed out that stimulation of T cells by antigen-nonspecific stimuli, most commonly through engagement of the TCR and costimulatory receptors with activating antibodies, may not mimic the more physiologic activation of these cells by a cognate antigen (11) .
Here, using the OT-I TCR transgenic system, we demonstrate that under antigen-specific stimulation conditions T-bet is required for the differentiation of naïve CD8 ϩ T cells into effector CTLs. T-bet-deficient CD8 ϩ cells fail to acquire a bona fide effector surface marker profile after antigenic stimulation, and, likewise, are severely impaired in their killing capacity. Similar to previous findings in CD4 ϩ T cells, T-bet-deficient OT-I, CD8 ϩ T cells proliferate and expand normally, but secrete low levels of IFN-␥, whereas IL-4, IL-2, and most strikingly, IL-10, production is elevated. Furthermore, the diminished cytotoxicity observed appears to be independent of the altered cytokine secretion pattern. Finally, in the absence of T-bet, in vivo CD8 ϩ -mediated responses after lymphocytic choriomeningitis virus (LCMV) infection and DNA vaccination are severely compromised.
Materials and Methods
Mice and Cell Lines. C57BL͞6 T-bet-deficient mice, backcrossed eight generations, were crossed onto the OT-I TCR transgenic background. IFN-␥-deficient OT-I mice were kindly provided by A. Lichtman (Harvard Medical School). The mouse thymoma, EL4, fibroblast line, MC57, and peritoneal exudate cells served as targets for CTL assays. ) were stimulated for 72 h in the presence of irradiated (2,000 rads) syngeneic C57BL͞6 splenocytes (15 ϫ 10 6 ) and 1 M ovalbumin peptide, SIINFEKL amino acids 257-264 (Sigma), or plate-bound anti-CD3 (2 g͞ml), anti-CD28 (2 g͞ml) with recombinant human IL-2 (100 units͞ml) then expanded for 4 days. Cells were then restimulated as above for 24 h by either irradiated splenocytes and peptide or plate-bound anti-CD3, and supernatants were collected for cytokine ELISA.
Intracellular Cytokine Staining and ELISA. Primary OT-I cultures were restimulated with either irradiated splenocytes and peptide for 18 h or combined phorbol 12-myristate 13-acetate (PMA) (50 ng͞ml) and ionomycin (1 M) for 5 h. The protein secretion inhibitor, monensin (3 M), was added to the cultures for the final 6 and 2 h, respectively. Cells were then washed, fixed in 4% paraformaldehyde, permeabilized with 0.1% saponin͞1% FCS͞ PBS, and stained with FITC-V␣2 and the appropriate PElabeled cytokine antibody. Culture supernatants were incubated overnight at 4°C in antibody-coated 96-well plates (Costar) for cytokine capturing. Plates were incubated sequentially with biotinylated secondary antibodies, avidin-horseradish peroxidase, and phosphatase substrate (Sigma) for detection.
In Vitro CTL Assay. OT-I, CD8 ϩ T cells were stimulated with irradiated splenocytes and peptide. After 72 h, cells were harvested, then incubated for 6 h with 51 Cr-labeled EL4 syngeneic targets (3,000 per reaction) pulsed with SIINFEKL peptide. Reactions were performed in triplicate at the indicated effector͞ target ratios. Nonspecific lysis was assessed at the 10:1 (effector͞ target) ratio without peptide loading, maximum lysis, by treating labeled targets with 1% SDS, and spontaneous lysis, in the absence of effectors. Specific lysis was calculated as described (12) .
In Vivo CTL Assay. T-bet OT-I) specific for the ovalbumin peptide, SIINFEKL (14) . CD8 cells were present at comparable numbers in WT and T-bet
OT-I transgenic thymus, spleen, and lymph node, indicating that T-bet is not required for the generation of the CD8 compartment. This finding is in contrast to mice lacking NFB activity caused by the overexpression of a dominant negative IB protein, which exhibit a block in the positive selection of CD8 ϩ thymocytes (15, 16) . We first examined the activation and effector differentiation status of stimulated T-bet (Fig. 1) . With proper activation, the surface of a CD8 ϩ T cell undergoes significant remodeling, resulting in a signature effector profile (17) . After stimulation with peptide in conjunction with antigen-presenting cells (APCs)͞peptide, WT OT-I CD8 ϩ T cells had elevated levels of CD25, CD44, CD69 and Ly-6C, while exhibiting considerable loss of CD62L expression. Although T-bet
OT-I CD8 ϩ T cells expressed levels of CD25 similar to WT, they demonstrated a slight reduction in CD44, incomplete elevation of CD69, failure to down-regulate CD62L, and virtually complete failure to up-regulate Ly-6C expression (Fig. 1a) . Of note, a fraction of the T-bet
OT-I CD8 ϩ population down-regulated CD8 expression after stimulation (data not shown). In addition, the differences in the signature effector profile seen with APC͞peptide stimulation were not reproduced with anti-CD3͞CD28-induced activation. The expression profiles of each marker were nearly identical upon polyclonal stimulation; notably, neither WT nor T-bet Ϫ/Ϫ CD8 cells down-regulated CD62L efficiently, whereas Ly6-C expression was dramatically up-regulated by cells of both genotypes (Fig. 1b) . These data demonstrate a substantial block in the antigen-driven generation of effector CTLs from naïve CD8 ϩ T cells in the absence of T-bet. Furthermore, this block appears to be bypassed by polyclonal activation. (18, 19) . In contrast to what we observed previously using antigen-nonspecific stimuli, T-bet
OT-I CD8
ϩ T cultures exhibited a profound reduction in both total IFN-␥ secretion and the number of IFN-␥-producing cells after APC͞peptide stimulation (Fig. 2a Upper) . However, these same T-bet
OT-I CD8 ϩ T cells produced only modestly diminished levels of IFN-␥ when stimulated by antibodies against the TCR and CD28 receptors, consistent with the surface marker profiles above and data previously reported (Fig. 2a Lower) . Similar to T-bet Ϫ/Ϫ CD4 ϩ T cells, the defect in IFN-␥ was accompanied by a substantial increase in the production of IL-4 ( Fig. 2b) and IL-5 (data not shown), even in the absence of Tc2 (IL-4, anti-IFN-␥, and anti-IL-12) polarizing conditions. T-bet has been reported to repress the transcription of the IL-2 gene in CD4 ϩ cells (6) . Similarly, T-bet
OT-I cells produced significantly higher amounts of IL-2 than WT controls (Fig. 2b) . Indeed the elevation in IL-2 production was far more pronounced in CD8ϩ than CD4 ϩ T-bet Ϫ/Ϫ cells and was also observed with greater reproducibility after APC͞peptide stimulation compared to other forms of activation. Of particular interest was the marked increase in levels of the Th2-associated immunosuppressive cytokine, IL-10, which is ordinarily secreted at very low levels in secondary stimulated CD8 ϩ T cells (Fig. 2b) . Intracellular cytokine staining confirmed the differing cytokine profiles observed. The T-bet Ϫ/Ϫ OT-I cultures exhibited a reduction in IFN-␥-producing cells and a concomitant increase in the number of cells producing IL-4 and IL-10 (Fig. 2c) . Differences in IL-2 intracellular staining were variable, although the levels of secreted IL-2 were consistently elevated in the absence of T-bet ( Fig. 2 b and c) .
In CD4 cells, T-bet acts at an early stage of Th differentiation to mold genetic programs in the naïve Th progenitor cell (6) . Interestingly, T-bet also acted at an early stage in the naïve CD8 cell to determine effector cell fate, as evidenced by the finding that the cytokine profiles of both WT and T-bet CD8 cells, stimulated with APC͞peptide in primary cultures, still showed pronounced differences in cytokine expression profiles after secondary stimulation either by APC͞peptide (Fig. 2c Right) or the polyclonal activity of PMA͞ionomycin (Fig. 2c Left) . Although CD8 ϩ Tc2 cells can be generated in vitro under Tc2-polarizing conditions, their frequency is much lower than CD4 ϩ Th2 populations, and their actual existence in vivo has been controversial. Our data suggest that one function of T-bet in CD8 cells in vivo may be to act as a potent repressor of the Tc2 phenotype. 
ϩ and WT OT-I CD8 ϩ cells in two separate antigen-specific assays. First, after in vitro priming with APC͞peptide for 72 h, CTL activity was quantified by chromium release from the thymoma cell line, EL4, pulsed with SIINFEKL peptide (12) . Although T-betdeficient CTLs displayed detectable cytolytic activity, the amount of cytolysis was greatly reduced across all effector͞target ratios when compared with WT CTLs (Fig. 3a) , a defect that could not be attributed to the impaired production of IFN-␥ (see below).
Cytolytic potential was also assessed by using an in vivo cross priming assay, as described by Robinson and colleagues (13) . WT and T-bet mock PBS. After 6 days, CFSE-labeled, peptide-pulsed target (bright) and unpulsed control (dim) splenocytes were coinjected i.v., and their survival was assessed by flow cytometry 10 h later. Consistent with the in vitro CTL assays, the number of peptidepulsed splenocytes recovered was markedly reduced in hosts that received WT OT-I CD8 ϩ T cells as compared to T-bet Ϫ/Ϫ OT-I CD8 ϩ recipients (Fig. 3b) . The impaired CTL activity could not be explained by defective proliferation or antigenic response of T-bet Ϫ/Ϫ CD8 ϩ T cells, as observed in mice lacking the transcription factor Runx3 (20) . CFSE-labeled T-bet Ϫ/Ϫ OT-I and WT OT-I CD8 ϩ T cells, transferred to C57BL͞6 hosts and immunized as above, progressed through a comparable number of cell divisions in response to antigen (Fig. 3c) . Furthermore we observed normal proliferation of T-bet Ϫ/Ϫ OT-I CD8 ϩ T cells after in vitro APC͞peptide stimulation (Fig. 3d) . Finally, TCR signaling in effector T cells results in the activation and serine phosphorylation of downstream mitogen-activated protein kinases, ERK1 and ERK2 (21) . Using an antibody specific for phosphorylated ERK1͞2, we observed comparable activation of ERK1͞2 in T-bet We considered that the diminished CTL activity observed in the absence of T-bet could be explained by the profoundly altered patterns of cytokine expression. IL-10 and IFN-␥ crossregulate each other in inflammatory responses and have been reported to play a central, although controversial, role in CD8 ϩ effector mechanisms (2, 22, 23) . Although in vitro-generated Tc2 cells have been reported to retain cytolytic activity, others have described conditions where CD8 T cells lose CTL function while producing elevated amounts of IL-4, IL-5, and IL-10 (24, 25) . Also, a deficiency in c-Rel expression that resulted in diminished CTL activity was overcome with the addition of exogenous cytokine (26) . To address this possibility, T-bet Ϫ/Ϫ OT-I and WT
ϩ T cells were cultured in the presence of exogenous recombinant cytokines (IFN-␥, IL-10), cytokine blocking antibodies and Tc1 (recombinant IL-12 and anti-IL-4), or Tc2 (IL-4, anti-IFN-␥ and anti-IL-12) skewing conditions. We observed no significant effects on CTL function in either WT or T-bet Ϫ/Ϫ OT-I CD8 ϩ T cells under any of the conditions tested (Fig. 3e and data not shown). To further address the role of IFN-␥ in CTL development, we examined CTL activity of IFN-␥-deficient OT-I transgenic CD8 ϩ T cells. Previous studies using such mutant mice have generated conflicting data on the role of IFN-␥ in viral infections (3, 27, 28) . Again, we observed only a modest reduction in the generation of SIINFEKL-specific CTL activity in the absence of IFN-␥ (Fig. 3a) . In addition, the cytolytic capacity of T-bet Ϫ/Ϫ , IFN-␥ Ϫ/Ϫ and WT OT-I CTLs was not altered by stimulation with IFN-␥-deficient splenocytes, ruling out the possibility that APC-derived IFN-␥ could overcome deficiencies in the generation of IFN-␥ Ϫ/Ϫ CTLs (data not shown). We conclude from these studies that T-bet controls the generation of effector CTLs by mechanisms beyond the regulation of IFN-␥, IL-4, and IL-10. Dissociation of IFN-␥ production from cytolytic activity has also been observed in mice lacking NFB activity caused by overexpression of a dominant negative IB protein that secrete normal levels of IFN-␥ yet do exhibit modest cytolytic defects (M. Boothby, personal communication) (16).
T-Bet Directs CD8 ؉ -Mediated Responses in Vivo.
Given the striking differences in T-bet function revealed by varying the mode of stimulation (antigen-specific vs. nonspecific polyclonal), it was critical to evaluate the function of T-bet in an in vivo immune response against a pathogen. Because T-bet is critical in the generation of CD4 -restricted LCMV epitope (31, 32) . A substantial reduction in numbers of IFN-␥ producer cells in the absence of T-bet was observed under both antigen-specific and polyclonal activation protocols, but was more pronounced in the former (Fig. 4a) . Cytolytic activity was examined 30 days after LCMV infection in secondary CTL assays after 6 days of culture with syngeneic LCMV-infected peritoneal exudate cells. Consistent with our observations using the OT-I TCR transgenic system, T-bet Ϫ/Ϫ LCMV-specific CD8 cells exhibited a marked decrease in cytotoxic effector function compared to WT and heterozygous controls (Fig. 4b) .
To further address CD8 effector function in vivo, we assessed the protective capacity of T-bet Ϫ/Ϫ CTLs after DNA vaccination (33) . It has been demonstrated that CTL clones can clear infection and that a vaccine that induced only CD8 cells was protective (34, 35) . T-bet Ϫ/Ϫ , T-bet ϩ/Ϫ , and WT mice received two injections of a DNA vector encoding for the LCMV nucleoprotein (pCMV-NP). Immunized and naïve, unimmunized control mice were then challenged with a normally lethal dose of LCMV by intracerebral inoculation. Within 10 days, nearly all T-bet Ϫ/Ϫ mice (8͞9) succumbed to infection, paralleling the course of naïve controls (10͞10). In contrast, a significant proportion of T-bet ϩ/Ϫ and T-bet ϩ/ϩ (6͞12) were completely protected (Fig. 4c) .
Discussion
Here, we have demonstrated that the generation and function of the effector CD8 ϩ T cell compartment relies on the transcription factor T-bet. Discovering the function of T-bet in CD8 effector cell generation relied solely on assays involving antigen-specific stimuli. Other studies, centered on Th cell differentiation, have revealed discrepancies when comparing varied activation protocols (11) . Indeed, although profound defects in T-bet Ϫ/Ϫ CD4 cells were observed under both antigen-specific and polyclonal stimulation, they were more marked in the former (7) . Although numerous reports have described common signaling pathways shared by CD4 and CD8 T cells, differing thresholds and requirements for activation of these subsets have been documented (36, 37) . For example, the exquisite sensitivity with which CD8 T cells can respond to minimal antigenic stimulations has been noted (38, 39) . Such considerations may have contributed to the initial masking and subsequent elucidation of a T-bet dependent phenotype in CD8 T cells. Like T-bet, other factors central to Th1 development could prove to be potent mediators of CTL differentiation when examined in an appropriate, antigen-specific setting.
This study establishes a vital role for T-bet, a transcription factor that controls Th1 development and activation, in CD8 ϩ effector function. T-bet therefore directs lineage commitment and effector function of naïve progenitor cells of both major T cell subsets, making it an overall regulator of type 1 immunity. This finding is in contrast to recent studies, which have described factors that play specific roles in CD8 ϩ but not CD4 effector function. For example, a deficiency in the runt domain transcription factor, Runx3, results in impaired CD8 ϩ T cell proliferation, despite normal expression of effector molecules like perforin, while having no effect on the proliferation of CD4 ϩ T cells (20) . Although deficiencies in other transcription factors (Ets1, GATA-3, TCF͞LEF1) result in profound developmental defects in both CD4 ϩ and CD8 ϩ T cells (40) , the specificity with which T-bet modulates the type 1 immune response within both cell types is unique. In Th cells, T-bet controls the production of cytokines, and hence effector function because this is the primary means by which CD4 cells mediate delayed type hyper- sensitivity and inflammatory responses. In CD8 cells, T-bet also controls cytokine production and effector function, but in T-betdeficient CD8 cells, these two functions are not linked.
Although roles in both CD4 and CD8 T cell function have been described, the mechanism by which T-bet directs effector differentiation in these two cell types is not fully understood. Recent studies have described T-bet-dependent gene expression in CD4 T cells (6, 11) . However, the altered cytokine production observed in T-bet-deficient CD8 T cells does not account for the loss of CD8 effector function. Therefore, a novel T-betdependent mechanism, either shared by both CD4 and CD8 T cells or one unique to the CD8 subset, must exist. Preliminary gene profiling experiments in T-bet Ϫ/Ϫ CTLs (unpublished observations) have almost exclusively revealed impaired expression of genes (e.g., perforin, granzyme B, and Fas ligand) known to be fundamental to effector CD8s (41) . Whether T-bet directly or indirectly regulates the expression of such genes remains to be established. T-bet should prove an attractive target in designing strategies to augment type 1 immunity against known and novel microorganisms.
